The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oikawa, Y.
Right arrow Articles by Saruta, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oikawa, Y.
Right arrow Articles by Saruta, T.
The Journal of Immunology, 2003, 171: 5865-5875.
Copyright © 2003 by The American Association of Immunologists

Systemic Administration of IL-18 Promotes Diabetes Development in Young Nonobese Diabetic Mice

Yoichi Oikawa*, Akira Shimada1,*, Akira Kasuga{dagger}, Jiro Morimoto*, Tadashi Osaki§, Hideaki Tahara{ddagger}, Tatsushi Miyazaki, Fumi Tashiro, Eiji Yamato, Jun-ichi Miyazaki and Takao Saruta*

* Department of Internal Medicine, Keio University School of Medicine, {dagger} Department of Internal Medicine, Tokyo Denryoku Hospital, and {ddagger} Department of Surgery, Institute of Medical Science, University of Tokyo, Tokyo, Japan; § Department of Molecular Medicine, Osaka University Graduate School of Medicine, and Division of Stem Cell Regulation Research, Area of Molecular Therapeutics, Course of Advanced Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

IL-18 is now identified as a pleiotropic cytokine that acts as a cofactor for both Th1 and Th2 cell development. Type 1 diabetes is considered a Th1-type autoimmune disease, and to date, the suppressive effect of exogenous IL-18 on the development of diabetes has been reported in 10-wk-old nonobese diabetic (NOD) mice. In the present study we administered exogenous IL-18 systemically in 4-wk-old NOD mice using i.m. injection of the IL-18 expression plasmid DNA (pCAGGS-IL-18) with electroporation. Contrary to previous reports, the incidence of diabetes development was significantly increased in NOD mice injected with pCAGGS-IL-18 compared with that in control mice. Systemic and pancreatic cytokine profiles deviated to a Th1-dominant state, and the the frequency of glutamic acid decarboxylase-reactive IFN-{gamma}-producing CD4+ cells was also high in the IL-18 group. Moreover, it was suggested that the promoting effect of IL-18 might be associated with increased peripheral IL-12, CD86, and pancreatic IFN-inducible protein-10 mRNA expression levels. In conclusion, we demonstrate here that IL-18 plays a promoting role as an enhancer of Th1-type immune responses in diabetes development early in the spontaneous disease process, which may contribute to elucidating the pathogenesis of type 1 diabetes.




This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
H. P. Carroll, V. Paunovic, and M. Gadina
Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity
Rheumatology, September 1, 2008; 47(9): 1269 - 1277.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zirlik, S. M. Abdullah, N. Gerdes, L. MacFarlane, U. Schonbeck, A. Khera, D. K. McGuire, G. L. Vega, S. Grundy, P. Libby, et al.
Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study
Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2043 - 2049.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. C. Lewis and C. A. Dinarello
Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor
PNAS, November 7, 2006; 103(45): 16852 - 16857.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella
IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway
J. Immunol., July 1, 2006; 177(1): 234 - 245.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Krogh-Madsen, P. Plomgaard, K. Moller, B. Mittendorfer, and B. K. Pedersen
Influence of TNF-{alpha} and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E108 - E114.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Shigihara, A. Shimada, Y. Oikawa, H. Yoneyama, Y. Kanazawa, Y. Okubo, K. Matsushima, E. Yamato, J.-i. Miyazaki, A. Kasuga, et al.
CXCL10 DNA Vaccination Prevents Spontaneous Diabetes through Enhanced {beta} Cell Proliferation in NOD Mice
J. Immunol., December 15, 2005; 175(12): 8401 - 8408.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Morimoto, H. Yoneyama, A. Shimada, T. Shigihara, S. Yamada, Y. Oikawa, K. Matsushima, T. Saruta, and S. Narumi
CXC Chemokine Ligand 10 Neutralization Suppresses the Occurrence of Diabetes in Nonobese Diabetic Mice through Enhanced {beta} Cell Proliferation without Affecting Insulitis
J. Immunol., December 1, 2004; 173(11): 7017 - 7024.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.